Nearly one-third of breast cancer survivors face relapse. Adopting healthy lifestyle habits—like proper diet, exercise, and ...

The biotechnology company said its Bria-IMT plus check point inhibitors showed a 17.3-month survival rate for patients with hormone receptor-positive breast cancer, exceeding the 14.4 months of ...

Bria-IMT plus check point inhibitors had a median overall survival which outperformed that of antibody-drug conjugates in HR+ ...